Premium
A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia
Author(s) -
GonzálezGascón y Marín Isabel,
HernándezSánchez María,
RodríguezVicente AnaEugenia,
Sanzo Carmen,
Aventín Anna,
Puiggros Anna,
Collado Rosa,
Heras Cecilia,
Muñoz Carolina,
Delgado Julio,
Ortega Margarita,
González MaríaTeresa,
Marugán Isabel,
Fuente Ignacio,
Recio Isabel,
Bosch Francesc,
Espinet Blanca,
González Marcos,
HernándezRivas JesúsMaría,
Hernández JoséÁngel
Publication year - 2016
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2196
Subject(s) - multivariate analysis , medicine , stage (stratigraphy) , chronic lymphocytic leukemia , gastroenterology , beta 2 microglobulin , cd38 , subgroup analysis , univariate analysis , leukemia , confidence interval , biology , paleontology , genetics , stem cell , cd34
The prognosis of chronic lymphocytic leukemia (CLL) patients displaying trisomy 12 (+12) remains unclear. In this study, we analyzed the influence of the proportion of cells with +12, and other clinical and biologic factors, in time to first therapy (TTFT) and overall survival (OS), in 289 patients diagnosed with CLL carrying +12. Median OS was 129 months. One hundred seventy‐four patients (60.2%) presented +12 in <60% of cells. TTFT and OS for this subgroup were longer than for the subgroup with +12 in ≥60% of cells, with a median TTFT of 49 months (CI95%, 39–58) vs 30 months (CI95%, 22–38) ( P = 0.001); and a median OS of 159 months (CI95%, 119–182), vs 96 months (CI95%, 58–134) ( P = 0.015). Other factors associated with a shorter TTFT were: Binet stage, B symptoms, lymphadenopathy, splenomegaly, high lymphocyte count, 11q‐, high β 2 microglobulin, and high LDH. In the multivariate analysis, clinical stage, +12 in ≥60% of cells, high lymphocyte count, B symptoms, and 11q‐ in addition, resulted of significance in predicting shorter TTFT. Significant variables for OS were: Binet stage, lymphadenopathy, splenomegaly, high LDH, high β 2 microglobulin, 11q‐, and CD38. In the multivariate analysis, only Binet stage, 11q‐, and high β2microglobulin significantly predicted shorter OS. CLL with +12 entails a heterogeneous group with intermediate prognosis. However, a high proportion of cells carrying +12 separates a subgroup of patients with poor outcome. Copyright © 2015 John Wiley & Sons, Ltd.